Page last updated: 2024-10-28

miltefosine and Melanoma

miltefosine has been researched along with Melanoma in 2 studies

miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.

Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Teymouri, M1
Farzaneh, H1
Badiee, A1
Golmohammadzadeh, S1
Sadri, K1
Jaafari, MR1
Ragnarsson-Olding, B1
Djureen-MÃ¥rtensson, E1
MÃ¥nsson-Brahme, E1
Hansson, J1

Other Studies

2 other studies available for miltefosine and Melanoma

ArticleYear
Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2015, Dec-01, Volume: 80

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Doxorubicin; Drug Delivery Syst

2015
Loco-regional control of cutaneous metastases of malignant melanoma by treatment with miltefosine (Miltex).
    Acta oncologica (Stockholm, Sweden), 2005, Volume: 44, Issue:7

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Melanoma; Neo

2005